{"id":1021811,"date":"2026-11-17T11:04:16","date_gmt":"2026-11-17T16:04:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/"},"modified":"2026-11-17T11:04:16","modified_gmt":"2026-11-17T16:04:16","slug":"nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/","title":{"rendered":"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion"},"content":{"rendered":"<h2>\nPositive Data Validate the Potential of NS002 in the Treatment of Anaphylaxis as Company Prepares to Initiate Pivotal Study in the Fourth Quarter of 2026<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">TEL AVIV, Israel, Nov.  17, 2026  (GLOBE NEWSWIRE) &#8212; <strong>Nasus Pharma Ltd. <\/strong>(NYSE: NSRX) (\u201cNasus Pharma\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced highlights of positive data presented at the American College of Allergy, Asthma and Immunology (\u201cACAAI\u201d) <em>2026 Annual Scientific Meeting<\/em>, held November 12-16 in Phoenix, Arizona. Results from the Company\u2019s NP007 trial, a Phase 2 study of NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, were selected for oral presentation in the \u201cDistinguish Industry and Late Breaking Abstracts\u201d session and as posters during the conference. Additional survey results of U.S. allergists on the importance of speed of onset in anaphylaxis were also presented.<\/p>\n<p align=\"justify\">The data presented at the ACAAI highlighted results from the NP007 study, which demonstrated that NS002 achieved faster time to therapeutic threshold as compared to an autoinjector. NS002 reached the 100 pg\/mL threshold sooner than the autoinjector after both single and repeat dosing. Potential superiority was also demonstrated against the autoinjector in conditions of severe nasal congestion. No serious adverse events were observed. Additional survey data of U.S. allergists showed that prescribers emphasize speed of onset and the proportion of patients reaching the therapeutic level within the first minutes as meaningful differences when considering therapeutic options.<\/p>\n<p align=\"justify\">\u201cWe believe the data presented to the allergy and immunology community at ACAAI represent an important validation of NS002 and the potential of our Nasax<sup>\u00ae<\/sup> platform,\u201d said Brendan O\u2019Grady, Chief Executive Officer of Nasus Pharma. \u201cWe are encouraged by these results, and confident in the program as we prepare to initiate the NS002 pivotal study before the end of 2026 and a topline data readout in the first quarter of 2027.\u201d<\/p>\n<p align=\"justify\">Detailed results and presentations are available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YXFD1OBkNCXFzeGSPbV9XSJbFqquUysOx5U5NhpOTy33sDi-jc0s6qvJk6nlOgEXe4YrAQjljhQot8FYpyIOE6xMrnyPwRBn5IpwTC3oJ0g=\" rel=\"nofollow\" target=\"_blank\">ACAAI website<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Nasus Pharma Ltd.<\/strong>\n      <\/p>\n<p align=\"justify\">Nasus Pharma is a clinical-stage pharmaceutical company developing a number of intranasal powder products addressing acute medical conditions in the community. NS002, Nasus Pharma\u2019s intranasal powder Epinephrine product candidate is being developed as a needle-free alternative to Epinephrine autoinjectors for patients with anaphylaxis. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers needle-free, easy-to-use alternatives. Nasus Pharma\u2019s proprietary powder-based intranasal (\u201cPBI\u201d) technology is designed for rapid and reliable drug delivery, leveraging the nasal cavity\u2019s rich vascular network for quick absorption. The PBI formulation uses uniform spherical powder particles for broad dispersion and potentially faster, higher absorption compared to liquid-based nasal products. For further information about the Company, please visit www.nasuspharma.com or follow on Twitter (X) or LinkedIn.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. federal securities laws. Words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill\u201d, \u201cwould,\u201d or the negative of these words, similar expressions or variations of such words are intended to identify forward-looking statements. For example, Nasus Pharma is using forward-looking statements in this press release when it discusses: the belief that the presentations made at ACAAI validate NS002 and demonstrate the potential of the Nasax\u00ae platform; the anticipated initiation of the NS002 pivotal study before the end of 2026; and the anticipation of the topline data readout in the first quarter of 2027. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Forward-looking statements are based on the Company\u2019s current expectations and are subject to uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2026. Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.<\/p>\n<p>\n        <strong>Corporate Contact<\/strong><br \/>\n        <br \/>Nasus Pharma Ltd. Israel<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AQ8qdlT-urIh_9uepJeXTvoC1fnFx_8dZaMH-quOsYsfH4Xjwd4qNrUcogMgqTcrmYDmTzhju9i1_jdVFKrX_TJqr4yL4HerNMHUp42BA04=\" rel=\"nofollow\" target=\"_blank\">info@nasuspharma.com<\/a><\/p>\n<p>\n        <strong>Investor<\/strong><br \/>\n        <strong>s<\/strong><br \/>\n        <strong> Contact<\/strong><br \/>\n        <br \/>Mike Moyer<br \/>LifeSci Advisors<br \/>+1-617-308-4306<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QPXjOPbuFRsb7-ZNEHbMwF_kIwjRUD1RRQpwbpEilxK86dmLPYU-hwoo0Gi3f6SIE1zcTfDXmeZbI7RwRkukyIxtYde_bbBgNH4WExmKzJfs2ULTrIHbD-Y6Kf1QqjVi\" rel=\"nofollow\" target=\"_blank\">mmoyer@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODQ5NzAxMWItNTNjYy00N2RkLThmMjQtYWQ3NDJkYzhmNGE2LTUwMDE1MDM0MS0yMDI2LTExLTE3LWVu\/tiny\/Nasus-Pharma-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Positive Data Validate the Potential of NS002 in the Treatment of Anaphylaxis as Company Prepares to Initiate Pivotal Study in the Fourth Quarter of 2026 TEL AVIV, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Nasus Pharma Ltd. (NYSE: NSRX) (\u201cNasus Pharma\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced highlights of positive data presented at the American College of Allergy, Asthma and Immunology (\u201cACAAI\u201d) 2026 Annual Scientific Meeting, held November 12-16 in Phoenix, Arizona. Results from the Company\u2019s NP007 trial, a Phase 2 study of NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, were selected for oral presentation in the \u201cDistinguish Industry and Late Breaking Abstracts\u201d session and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1021811","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Positive Data Validate the Potential of NS002 in the Treatment of Anaphylaxis as Company Prepares to Initiate Pivotal Study in the Fourth Quarter of 2026 TEL AVIV, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Nasus Pharma Ltd. (NYSE: NSRX) (\u201cNasus Pharma\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced highlights of positive data presented at the American College of Allergy, Asthma and Immunology (\u201cACAAI\u201d) 2026 Annual Scientific Meeting, held November 12-16 in Phoenix, Arizona. Results from the Company\u2019s NP007 trial, a Phase 2 study of NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, were selected for oral presentation in the \u201cDistinguish Industry and Late Breaking Abstracts\u201d session and &hellip; Continue reading &quot;Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T16:04:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion\",\"datePublished\":\"2026-11-17T16:04:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/\"},\"wordCount\":757,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/\",\"name\":\"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==\",\"datePublished\":\"2026-11-17T16:04:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/","og_locale":"en_US","og_type":"article","og_title":"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion - Market Newsdesk","og_description":"Positive Data Validate the Potential of NS002 in the Treatment of Anaphylaxis as Company Prepares to Initiate Pivotal Study in the Fourth Quarter of 2026 TEL AVIV, Israel, Nov. 17, 2026 (GLOBE NEWSWIRE) &#8212; Nasus Pharma Ltd. (NYSE: NSRX) (\u201cNasus Pharma\u201d or the \u201cCompany\u201d), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced highlights of positive data presented at the American College of Allergy, Asthma and Immunology (\u201cACAAI\u201d) 2026 Annual Scientific Meeting, held November 12-16 in Phoenix, Arizona. Results from the Company\u2019s NP007 trial, a Phase 2 study of NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, were selected for oral presentation in the \u201cDistinguish Industry and Late Breaking Abstracts\u201d session and &hellip; Continue reading \"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-17T16:04:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion","datePublished":"2026-11-17T16:04:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/"},"wordCount":757,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/","name":"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==","datePublished":"2026-11-17T16:04:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3ODkxOSM3OTY4OTYzIzUwMDE1MDM0MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nasus-pharma-presents-data-at-acaai-2026-demonstrating-ns002-reached-the-therapeutic-epinephrine-threshold-faster-than-an-autoinjector-after-repeat-dosing-and-under-severe-nasal-congestion\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nasus Pharma Presents Data at ACAAI 2026 Demonstrating NS002 Reached the Therapeutic Epinephrine Threshold Faster Than an Autoinjector After Repeat Dosing and Under Severe Nasal Congestion"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1021811"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1021811\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1021811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1021811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1021811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}